隐球菌性脑膜炎
医学
临床终点
内科学
氟康唑
队列
抗真菌
代理终结点
人类免疫缺陷病毒(HIV)
脑膜炎
队列研究
免疫学
临床试验
外科
病毒性疾病
皮肤病科
作者
Tihana Bicanic,Conrad Muzoora,Annemarie E. Brouwer,Graeme Meintjes,Nicky Longley,Kabanda Taseera,Kevin Rebe,Angela Loyse,Joseph N Jarvis,Linda‐Gail Bekker,Robin Wood,Direk Limmathurotsakul,Wirongrong Chierakul,Kasia Stepniewska,Nicholas J. White,Shabbar Jaffar,Thomas S. Harrison
摘要
BACKGROUND: Progress in therapy for cryptococcal meningitis has been slow because of the lack of a suitable marker of treatment response. Previously, we demonstrated the statistical power of a novel endpoint, the rate of clearance of infection, based on serial quantitative cultures of cerebrospinal fluid, to differentiate the fungicidal activity of alternative antifungal drug regimens. We hypothesized that the rate of clearance of infection should also be a clinically meaningful endpoint. METHODS: We combined data from cohorts of patients with human immunodeficiency virus-associated cryptococcal meningitis from Thailand, South Africa, and Uganda, for whom the rate of clearance of infection was determined, and clinical and laboratory data prospectively collected, and explored the association between the rate of clearance of infection and mortality by Cox survival analyses. RESULTS: The combined cohort comprised 262 subjects. Altered mental status at presentation, a high baseline organism load, and a slow rate of clearance of infection were independently associated with increased mortality at 2 and 10 weeks. Rate of clearance of infection was associated with antifungal drug regimen and baseline cerebrospinal fluid interferon-gamma levels. CONCLUSIONS: The results support the use of the rate of clearance of infection or early fungicidal activity as a means to explore antifungal drug dosages and combinations in phase II studies. An increased understanding of how the factors determining outcome interrelate may help clarify opportunities for intervention.
科研通智能强力驱动
Strongly Powered by AbleSci AI